Healthcare [ 4/11 ] | Biotechnology [ 50/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.52 Increased by +157.78% | 0.29 Increased by +79.31% |
| May 12, 23 | -1.37 Decreased by -52.22% | -0.13 Decreased by -953.85% |
| Mar 30, 23 | 1.23 Increased by +236.67% | -0.15 Increased by +920.00% |
| Nov 15, 21 | -0.75 Increased by +16.67% | -0.75 |
| Aug 16, 21 | -0.90 Increased by +45.45% | -0.90 |
| May 17, 21 | -0.90 Increased by +25.00% | -0.90 |
| Mar 31, 21 | -0.90 Increased by +81.82% | -0.90 |
| Nov 4, 20 | -0.90 Increased by +57.14% | -1.50 Increased by +40.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.01 M Decreased by -564.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -8.71 M Decreased by -204.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 5.01 M Increased by +176.57% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -660.00 K Increased by +24.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -603.00 K Increased by +36.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -2.86 M Decreased by -186.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -6.55 M Decreased by -559.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -871.00 K Increased by +15.27% | Decreased by N/A% Decreased by N/A% |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.